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Abstract
Background: Nutrient deprivation, hypoxia, radiotherapy and chemotherapy induce endoplasmic reticulum (ER)
stress, which activates the so-called unfolded protein response (UPR). Extensive and acute ER stress directs the UPR
towards activation of death-triggering pathways. Cancer cells are selected to resist mild and prolonged ER stress by
activating pro-survival UPR. We recently found that drug-resistant tumor cells are simultaneously resistant to ER
stress-triggered cell death. It is not known if cancer cells adapted to ER stressing conditions acquire a
chemoresistant phenotype.
Methods: To investigate this issue, we generated human cancer cells clones with acquired resistance to ER stress
from ER stress-sensitive and chemosensitive cells.
Results: ER stress-resistant cells were cross-resistant to multiple chemotherapeutic drugs: such multidrug resistance
(MDR) was due to the overexpression of the plasma-membrane transporter MDR related protein 1 (MRP1). Gene
profiling analysis unveiled that cells with acquired resistance to ER stress and chemotherapy share higher
expression of the UPR sensor protein kinase RNA-like endoplasmic reticulum kinase (PERK), which mediated the
erythroid-derived 2-like 2 (Nrf2)-driven transcription of MRP1. Disrupting PERK/Nrf2 axis reversed at the same time
resistance to ER stress and chemotherapy. The inducible silencing of PERK reduced tumor growth and restored
chemosensitivity in resistant tumor xenografts.
Conclusions: Our work demonstrates for the first time that the adaptation to ER stress in cancer cells produces a
MDR phenotype. The PERK/Nrf2/MRP1 axis is responsible for the resistance to ER stress and chemotherapy, and may
represent a good therapeutic target in aggressive and resistant tumors.
Keywords: Eukaryotic translation initiation factor-2α kinase 3/protein kinase RNA-like endoplasmic reticulum kinase,
Multidrug resistance related protein 1, Endoplasmic reticulum stress, Unfolded protein response, Chemoresistance
Background
Cancer cells often face conditions of nutrient deprivation,
hypoxia, alterations in glycosylation status and calcium
flux [1, 2], leading to the accumulation of unfolded or mis-
folded proteins in the endoplasmic reticulum (ER) lumen.
These conditions activate the so-called unfolded protein
response (UPR; [3, 4]). In the early phase, UPR mediates
the adaptation to stress by modifying the transcrip-
tional and translational programs responsible for pro-
tein folding, and/or by promoting ER-associated
degradation (ERAD) pathways to remove misfolded
proteins. If the attempt to adapt to ER stress fails, the
UPR activates cell death programs to eliminate the
damaged cells [5, 6]. Recently, we demonstrated that
cancer cells with constitutive or acquired resistance to
chemotherapy are also resistant to ER stress-triggered
cell death. This resistance was due to ubiquitination
and subsequent degradation of the ER stress-activated
transcription factor CAAT/enhancer-β liver-enriched
* Correspondence: joanna.kopecka@unito.it; chiara.riganti@unito.it
Iris C Salaroglio and Elisa Panada were co-first authors.
Joanna Kopecka and Chiara Riganti were co-last authors
†Equal contributors
1Department of Oncology, University of Torino, via Santena 5/bis, 10126
Torino, Italy
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Salaroglio et al. Molecular Cancer  (2017) 16:91 
DOI 10.1186/s12943-017-0657-0
inhibitory protein (C/EBP-β LIP). Consequently, the pro-
apoptotic axis C/EBP homologous protein (CHOP)/cas-
pase 3 was down-regulated in the resistant cells. Moreover,
LIP elimination in the chemoresistant cells up-regulates
the transcription of P-glycoprotein (Pgp) [7]. Pgp prevents
the accumulation of chemotherapeutic drugs and targeted
therapy-agents, determining multidrug resistance (MDR)
[8]. Since many chemotherapeutic drugs – such as anthra-
cyclines [9], cisplatin [10], oxaliplatin [9], 5-fluorouracil
[11] and paclitaxel [12] – induce a massive ER-stress medi-
ated cell death, the lack of ER stress-dependent apoptotic
response coupled with the increased drug efflux strongly
reduces the efficacy of these drugs in MDR cells.
Three sensors of ER stress - activating transcription
factor 6 (ATF6), inositol-requiring enzyme 1 (IRE1) and
protein kinase RNA-like endoplasmic reticulum kinase/
eukaryotic translation initiation factor-2α kinase 3 (PERK) -
initiate the UPR in cancer cells [3, 13]. Activated PERK
phosphorylates eukaryotic translation initiation factor-2α
(EIF2α) and nuclear factor erythroid-derived 2-like 2 (Nrf2),
thereby attenuating protein translation and inducing genes
controlling redox homeostasis [13, 14]. The activation of
PERK may determine resistance to ER stress-induced cell
death in a EIF2α-dependent manner [6, 13] and resistance
to chemotherapy-induced cell death in a Nrf2-dependent
manner [15–18]. By binding antioxidant response elements
(AREs) in promoter regions, Nrf2 up-regulates antioxidant
genes, metal-binding proteins, stress response proteins,
drug-metabolizing enzyme and drug efflux transporters
such as MDR-related protein 1 (MRP1) [16, 19].
While our previous findings suggest that cells with
acquired resistance to chemotherapy are also resistant to
ER stress-dependent cell death, it is not known whether
chemosensitive cancer cells adapted to ER stress acquire
resistance to chemotherapy as well. To address this issue,
we exposed ER stress-sensitive/chemosensitive cancer cells
to 3 different ER stress inducers developing the corre-
sponding ER stress-resistant clones. We demonstrated that
the activation of PERK/Nrf2/MRP1 axis determines the re-
sistance to ER stress and also resistance to chemotherapy.
Inhibiting this axis is an effective anti-proliferative and
chemosensitizing strategy.
Methods
Chemicals and supplies
Cell culture plasticware were obtained from Falcon
(Becton Dickinson, Franklin Lakes, NJ). Gel electro-
phoresis reagents were obtained from Bio-Rad La-
boratories (Hercules, CA). The protein content of
cell lysates was measured with the BCA kit from
Sigma Chemicals Co. (St. Louis, MO) using bovine
serum albumin as a standard. Unless specified other-
wise, all other reagents were purchased from Sigma
Chemical Co.
Cells
Human chemosensitive colon cancer HT29 cells (ATCC,
Manassas, VA) were cultured in RPMI-1640 medium sup-
plemented with 10% fetal bovine serum (FBS, Invitrogen
Life Technologies, Carlsbad, CA) and 100 U/ml penicillin,
100 μg/ml streptomycin. HT29/MDR cells, a subpopula-
tion of HT29 cells displaying resistance to chemotherapy
and ER stress inducers (Additional file 1: Table S1), were
obtained as reported [7]. ER stress-resistant subpopula-
tions, termed HT29/Tg, HT29/Tun and HT29/Bfa, were
created by stepwise selection of parental HT29 cells in
RPMI-1640 medium containing increasing concentrations
of thapsigargin, tunicamycin and brefeldin A, respectively.
Resistant subclones were then maintained at a concentra-
tion of each ER stress inducer that allowed > 95% cell via-
bility (500 nM thapsigargin, 250 nM tunicamycin and 250
nM brefeldin A). ER stress-resistant clones were similarly
derived from human chemosensitive breast cancer MCF7
cells and human chemosensitive osteosarcoma U-2OS
cells (ATCC). MCF7/Tun and U-2OS/Tun were main-
tained in DMEM/F12 and IMDM medium (Invitrogen
Life Technologies), supplemented with 10% FBS, 100 U/
ml penicillin, 100 μg/ml streptomycin, containing 500 nM
tunicamycin. When cultured in 3D-systems, 1 × 105 cells
were seeded in 96-well plate coated with Biomimesys™
matrix (Celenys, Rouen, France). After 7 days, 3D-cultures
were treated and analyzed by contrast phase Leica DC100
microscope (Leica Microsystems GmbH, Wetzlar,
Germany; 10X ocular lens, 4X objective). Cell lines were
authenticated by microsatellite analysis using the Power-
Plex kit (Promega Corporation, Madison, WI; last authen-
tication: September 2016).
Measurement of cell necrosis and cell viability
Cells were incubated for 24 h (for the High Mobility Group
Protein 1, HMGB1, assay) or 48 h (for Neutral red and
crystal violet staining) in fresh medium, or in medium con-
taining thapsigargin (10 μM), tunicamycin (1 μM), brefeldin
A (1 μM), or the chemotherapeutic drugs oxaliplatin or cis-
platin (10 μM), 5-fluorouracil (5 μM), doxorubicin (5 μM).
Acute cell toxicity was measured by evaluating the release
of HMGB1 in the cell culture supernatant, using the High
Mobility Group Protein 1 ELISA kit (Cloud-Clone Corp.,
Houston, Texas). Results were expressed in pg/mg total
cellular protein, employing a pre-made titration curve. Cell
viability was measured using Neutral red staining assay [7].
The viability of untreated cells was considered 100%; the
results were expressed as percentage of viable cells in each
experimental condition versus untreated cells. IC50 was
calculated by incubating cells with increasing concentra-
tions of the drugs (from 10−10 to 10- 3 M), then staining
cells with Neutral red. To evaluate morphology, cells were
stained with 5% w/v crystal violet solution in 66% v/v
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methanol, washed and analyzed under bright field micro-
scope (10X objective; 10X ocular lens).
Immunoblotting
Cells were rinsed with ice-cold lysis RIPA buffer (50 mM
Tris, 10 mM EDTA, 1% v/v Triton-X100; pH 7.5), supple-
mented with the protease inhibitor cocktail set III (80 μM
aprotinin, 5 mM bestatin, 1.5 mM leupeptin, 1 mM
pepstatin; Calbiochem, San Diego, CA), 2 mM phenyl-
methylsulfonyl fluoride and 1 mM Na3VO4. The cells
were then sonicated (10 bursts of 10 s, 4 °C, 100 W, using
a Labsonic sonicator, Hielscher, Teltow, Germany) and
centrifuged at 13,000 × g for 10 min at 4 °C. 20 μg protein
extracts were subjected to 4-20% gradient SDS-PAGE and
probed with the following antibodies: anti-Pgp (1:500;
Calbiochem); anti-MRP1 (1:500; Abcam, Cambridge, UK);
anti-MRP2 (1:250; Abcam); anti-MRP3 (1:500; Santa Cruz
Biotechnology Inc., Santa Cruz, CA); anti-MRP4 (1:250;
Santa Cruz Biotechnology Inc.); anti-MRP5 (1:500;
Abcam); anti-BCRP (1:1000; Santa Cruz Biotechnology
Inc.), anti-PERK (1:500; Santa Cruz Biotechnology Inc.),
anti-IRE1 (1:500; Thermo Scientific Inc., Rockford, IL),
anti-ATF6 (1:500; Santa Cruz Biotechnology Inc.), anti-
eIF2α (1:1000; Abcam), anti-phospho(Ser51)eIF2α (1:500;
Abcam), anti-β-tubulin (1:1000; Santa Cruz Biotechnol-
ogy Inc.). The membranes were then incubated with
peroxidase-conjugated secondary antibody (1:3000; Bio-
Rad Laboratories) and washed with Tris-buffered saline-
Tween 0.1% v/v solutions. Protein bands were detected by
enhanced chemiluminescence (Bio-Rad Laboratories).
Nuclear extracts were prepared using the Nuclear Extract
kit (Active Motif, La Hulpe, Belgium). Nuclear proteins
were separated by SDS-PAGE and probed with anti-Nrf2
(1:500; Abcam) or anti-TATA box binding protein anti-
bodies (TBP, 1:500; Santa Cruz Biotechnology Inc.).
Quantitative Real Time-PCR (qRT-PCR) and PCR expression
arrays
Total RNA was extracted and reverse-transcribed using
the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories).
qRT-PCR was performed using IQ™ SYBR Green Super-
mix (Bio-Rad Laboratories). The same cDNA preparation
was used for measuring genes of interest and the house-
keeping gene S14. The primer sequences, designed with
qPrimerDepot software (https://primerdepot.nci.nih.gov/),
are reported in the Additional File 2. Relative gene expres-
sion levels were calculated using Gene Expression Quanti-
tation software (Bio-Rad Laboratories). PCR arrays were
generated using 1 μg cDNA and Human Unfolded Protein
Response Plus RT2 Profiler™ PCR Array (Bio-Rad Labora-
tories) according to the manufacturer’s instructions. Data
analysis was performed using the PrimePCR™ Analysis
Software (Bio-Rad Laboratories).
Flow cytometry
Cells (1 × 106) were rinsed and fixed with 2% w/v para-
formaldehyde for 2 min, permeabilized using 0.1% v/v
Triton-X100 for 2 min on ice, washed three times with
PBS and stained with an anti-MRP1 antibody (1:250,
Abcam) for 1 h on ice. The cells were then incubated
with an AlexaFluor 488-conjugated secondary antibody
(1:100, Millipore, Billerica, MA) for 30 min and washed
again. Samples were analyzed with a FACS-Calibur flow
cytometer (Becton Dickinson). For each analysis 10000
events were collected. Control experiments included
incubation with non immune isotype antibody followed
by the secondary antibody. The results were expressed
as mean fluorescence value of MRP1 expression, calcu-
lated with the Cell Quest software (Becton Dickinson).
Intracellular doxorubicin accumulation
Doxorubicin content was measured by fluorimetry as
detailed elsewhere [20]. The results were expressed as
nmol doxorubicin/mg cell proteins, according to a pre-
formed titration curve.
Chromatin immunoprecipitation (ChIP)
ChIP experiments were performed for determining
binding of Nrf2 to the ARE1 site of the MRP1 promoter
[21]. The PCR primers used were: 5’-CGGCTCGAGT
TATCATGTCTCCAGGCTTCA-3’; 5’-CGGAAGCTTG
CCGGTGGCGCGGG-3’.
PERK silencing
Cells (2 × 106 in 0.25 mL FBS/antibiotic-free medium)
were transduced with 6 × 105 lentiviral particles (Thermo
Scientific Open Biosystems, Waltham, MA). 6 h after
the transfection, 0.25 mL complete medium was added.
Medium was fully replaced 24 h after the transfection.
Transfection efficiency was checked by evaluating the
percentage of green fluorescent protein (GFP)-positive
cells by fluorescence microscopy, 48 h after the transfec-
tion: in each experiment, GFP-positive cells were ≥90%.
Stably transduced clones were selected by culturing cells
in medium containing 2 μg/mL puromycin, for 3 weeks.
PERK shRNA was induced by adding 1 μg/mL doxycyc-
line to the culture medium for 72 h. To verify the silen-
cing efficacy, cells were lysed and PERK was visualized
by immunoblotting, as described above.
In vivo tumor growth
HT29 cells or HT29/MDR cells (1 × 106) transduced
with the inducible silencing vector for PERK, were re-
suspended in 100 μL culture medium, mixed with
100 μL Matrigel and injected s.c. into 6–8 weeks old
NOD SCID BALB/c female mice (weight: 20.82 ±
2.34 g), housed under 12 h light/dark cycle, with food
and drinking provided ad libitum. Tumor growth was
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measured daily by caliper, and was calculated according
to the equation (LxW2)/2, where L = tumor length and
W= tumor width. When tumor reached the volume of
100 mm3, mice were randomized and treated on day 3,
9, 15 as it follows: 1) Ctrl group was treated with 200 μL
saline solution i.v.; 2) oxaliplatin (oPt) group was treated
with 5 mg/Kg oPt i.p. Intratumor PERK silencing was
activated by doxycycline (2 mg/mL) in the drinking
water. Animals were euthanized at day 21. Tumors were
resected, photographed and fixed in 4% v/v paraformal-
dehyde. The paraffin sections were stained with
hematoxylin/eosin or immunostained for PERK (1:50),
MRP1 (1:50), cleaved caspase 3 (Asp175, 1:50; Cell
Signaling Technology Inc., Danvers, MA), followed by a
peroxidase-conjugated secondary antibody (1:100, Dako,
Glostrup, Denmark). Sections were examined with a
Leica DC100 microscope (Leica Microsystems GmbH,
Wetzlar, Germany; 10X ocular lens, 63X objective).
Cell migration
In vitro migration was evaluated by the scratch wound
healing assay over a period of 24 h, as reported [22].
Results were expressed as μm/h, by performing ≥ 100
measurement per each condition.
Statistical analysis
All data in text and figures are provided as means ± SD.
The results were analyzed by a one-way Analysis of Vari-
ance (ANOVA). p < 0.05 was considered significant.
Gene expression profiles and clinical data were ob-
tained from The Cancer Genome Atlas (TCGA; https://
cancergenome.nih.gov/) and analysed using R (https://
www.R-project.org). Survival association analyses were
performed using Cox's proportional hazard model in
univariate setting and Kaplan-Meier method, applying
false discovery rate (FDR) and Bonferroni correction for
multiple testing.
Results
Cells adapted to ER stress acquire resistance to
chemotherapy
Chemosensitive human colon cancer HT29 and its che-
moresistant clone HT29/MDR were incubated with the ER
stress inducers thapsigargin, tunicamycin or brefeldin A, or
with the chemotherapeutic agents oxaliplatin (a substrate
of MRP1 and MRP4), 5-fluorouracil (a substrate of MRP1,
MRP3, MRP4 and MRP5) or doxorubicin (a substrate of
Pgp, MRP1, MRP2, MRP3 and BCRP), at concentrations
that were cytotoxic in chemosensitive cells but not in che-
moresistant ones ([7]; Additional file 1). Cytotoxicity was
characterized by release of HMGB1 to the culture media
and by reduced cell viability (Fig. 1a-f). To verify whether
cells resistant to ER stress were also cross-resistant to
chemotherapy, we generated the ER stress resistant clones
HT29/Tg, HT29/Tun, HT29/Bfa from the ER stress-
sensitive/chemosensitive HT29 cells. In these clones
neither ER stress inducers nor chemotherapeutic agents
increased the release of HMGB1 (Fig. 1a, b) or reduced cell
viability (Fig. 1c-f). Resistance to oxaliplatin, chosen as a
paradigmatic first-line treatment in colon cancer, was
preserved in 3D-cultures of HT29/MDR and HT29/Tun
cells (Additional file 3). Overall, these data suggest that the
acquisition of resistance to ER stress is associated to the
acquisition of resistance to chemotherapy.
ER stress- and chemotherapy-resistant cells up-regulate
MRP1
Chemoresistance is often mediated by increased expression
of ABC transporters [8]. Therefore, we analyzed their
expression level in chemosensitive/ER stress-sensitive
HT29 cells and in the HT29/Tg, HT29/Tun and HT29/Bfa
clones. HT29/MDR were used as control of chemoresis-
tant/ER-stress resistant cells overexpressing Pgp, MRP1,
MRP2, MRP3, MRP5 and BCRP. Compared to HT29 cells,
all the ER stress-resistant clones showed higher expression
of MRP1 at the protein (Fig. 2a) and mRNA (Fig. 2b) levels,
associated with a higher amount of MRP1 on the cell
surface (Fig. 2c-d). In line with this trend, the intracellular
accumulation of doxorubicin, which is inversely related to
MRP1 activity, was lower in the ER-stress resistant clones,
as well as in HT29/MDR cells (Fig. 2e).
To verify whether the cross resistance to ER stress
inducers and to chemotherapeutic drugs was limited to
HT29 cells or not, we generated two other ER stress-
resistant clones, MCF7/Tun and U-2OS/Tun, from ER
stress-sensitive/chemosensitive breast cancer MCF7 cells
and osteosarcoma U-2OS cells. As for HT29 subclones,
MCF7/Tun and U-2OS/Tun cells were resistant to both
ER stress inducers and to chemotherapeutic drugs. These
cells exhibited higher expression of MRP1 protein and
mRNA, higher amount of MRP1 on cell surface, and
lower retention of doxorubicin (Additional files 4 and 5).
These data suggested that up-regulation of MRP1 is asso-
ciated with the dual resistance to ER stress and to chemo-
therapy and is exhibited by a variety of cancer cells of
different histological origin.
The PERK/Nrf2 axis up-regulates MRP1 and controls the
resistance to ER stress and to chemotherapy
To investigate whether there is a common gene signature
between chemoresistant cells and ER stress-resistant cells,
we compared the expression of 83 genes involved in UPR
in HT29/Tun, HT29/MDR and HT29 cells.
As expected, several genes involved in protein synthesis,
ER quality control and ERAD were significantly up-
regulated in HT29/Tun cells (Fig. 3a; Additional file 6). By
contrast, only PERK was significantly increased in HT29/
MDR cells (Fig. 3b; Additional file 6). Interestingly, the fold-
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increase of PERK mRNA in HT29/Tun and HT29/MDR
cells was very similar (Fig. 3a, b; Additional file 6) and was
associated with increased PERK protein levels (Fig. 3c). No
appreciable change in the expression of the other ER stress
sensors IRE1 and ATF6 was observed (Fig. 3c).
In line with previous findings [13, 14], the highly
PERK-expressing HT29/MDR, HT29/Tg, HT29/Tun and
HT29/Bfa cells had higher mRNA levels of the PERK-
target/redox-sensitive factor Nrf2 (Fig. 3d). Nrf2 protein
was also more translocated in the nucleus (Fig. 3e) and
it was bound to the ABCC1/MRP1 promoter (Fig. 3e).
Overall, these data suggest that the increase of MRP1
expression in cells resistant to ER stress and to chemo-
therapy is associated to up-regulation of PERK and Nrf2.
Targeting the PERK/Nrf2/MRP1 axis abrogates the dual
resistance to ER stress and chemotherapy
We next generated HT29/MDR, HT29/Tg, HT29/Tun,
HT29/Bfa clones transduced with a doxycycline-inducible
shRNA for PERK. In parallel, we treated these clones with
the MEK/ERK inhibitor PD98059, which prevents the
phosphorylation and transcriptional activity of Nrf2 in
colon cancer [23]. As expected, the silencing of PERK re-
duced the phosphorylation on serine 51 of eIF2α (Fig. 4a),
a typical PERK substrate [13]. Both PERK-silenced cells
and PD98059-treated cells showed decreased nuclear
translocation of Nrf2 (Fig. 4b), MRP1 mRNA level
(Fig. 4c) and MRP1 amount on the cell surface (Fig. 4d;
Additional file. 7a, b), coupled with increased doxorubicin
accumulation (Fig. 4e).
Direct downstream targets of PERK, selected using
GeneOntology database (www.geneontology.org/), such
as eukaryotic translation initiation factor 2 subunit
1 (EIF2S1), activating transcription factor 4 (ATF4), and
Nrf2 (13, 14; Additional file 8a), were up-regulated in
HT29/MDR and HT29/Tun cells (Additional file 8b), in
accord with the increased amount of PERK in these
cells. PERK-silencing significantly reduced the expression
Fig. 1 Drug resistance of human colon cancer cells adapted to ER stress. a, b. Release of the necrosis marker HMGB1 to culture media of the
indicated cells (human chemosensitive HT29 cells, chemoresistant HT29/MDR cells, ER stress-resistant clones HT29/Tg, HT29/Tun, HT29/Bfa),
following incubation in fresh medium (Ctrl), or in media containing: thapsigargin (Tg), tunicamycin (Tun), brefeldin A (Bfa), oxaliplatin (oPt),
5-fluorouracil (5FU), doxorubicin (Dox), as indicated in Methods. Data are mean ± SD. (n = 3). *p < 0.001 for treated cells vs. Ctrl HT29 cells.
°p < 0.001 for HT29/MDR, HT29/Tg, HT29/Tun/HT29/Bfa cells vs. the corresponding condition in HT29 cells. c, d. Viability of cells measured
by Neutral red staining. Data are mean ± SD (n = 4). *p < 0.02 for treated cells vs. Ctrl HT29 cells; °p < 0.05 for HT29/MDR, HT29/Tg, HT29/Tun/
HT29/Bfa cells vs. the corresponding condition in HT29 cells. e, f. Crystal violet staining of cells grown in 96-well plates and treated as in a and
b. The images are representatives of at least 5 microscopic fields showing similar cell density. Bars = 500 μM
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levels of all these genes (Additional file 8b). Other up-
stream controllers of Nrf2 such as glycogen synthase
kinase 3β (GSK3β), c-Jun N-terminal kinase 1 (JNK1),
mitogen activated kinase 1 (MAPK1), phosphatidylinositol-
4,5-bisphosphate 3-kinase catalytic subunit δ (PI3KCD),
protein kinase Cα (PRKCA), were increased in HT29/
MDR and HT29/Tun cells, but variably modulated by
PERK-silencing, likely because multiple pathways control
the transcription of these genes. We also analyzed the
expression of Nrf2-target genes (www.geneontolo-
gy.org/), divided into two main categories: 1) genes
encoding for anti-oxidant/detoxifying enzymes and
chaperones, such as glutathione-disulfide reductase (GSR),
glucose-6-phosphate dehydrogenase (G6PD), thioredoxin
reductase 1 (TXNRD1), superoxide dismutase 1 (SOD1),
heme oxygenase 1 (HMOX1), NAD(P)H quinone de-
hydrogenase 1 (NQO1), stress induced phosphoprotein 1
(STIP1); 2) genes encoding for membrane efflux trans-
porters like MRP1 (Additional file 8a). All these genes
were significantly up-regulated in HT29/MDR cells and
HT29/Tun cells and significantly down-regulated in both
populations by either PERK-silencing or Nrf2-inhbition
(Additional file 8b).
The inducible silencing of PERK increased the release of
HMGB1 (Fig. 5a, b) and reduced cell survival (Fig. 5c-e).
ER stress inducers and chemotherapeutic drugs enhanced
the effect of PERK silencing in all the resistant clones
(Fig 5). Similar effects were observed upon inhibition of
Nrf2 (Additional file 9a-d).
Since the expression of PERK and NRF2 is variably
related to patient clinical outcome (Additional file 10),
to better clarify the impact of PERK on tumor progres-
sion and response to therapy in a preclinical model, we
implanted HT29/MDR cells transduced with inducible
shRNA for PERK in NOD SCID BALB/c mice, treated
with oxaliplatin, with or without doxycycline. HT29 cells
were implanted to establish a control oxaliplatin-sensitive
tumor. HT29/MDR cells generated tumors faster than
HT29 cells (Fig. 6a; Additional file 11). Although we did
not detect significant differences in the proliferation rate
Fig. 2 Expression of MRP1 in cells resistant to chemotherapy and to ER stress. a. Immunoblots of the indicated proteins in extracts of untreated cells.
β-tubulin was used as a loading control. The figure is representative of 3 experiments with similar results. b. MRP1 mRNA level as measured by qRT-
PCR. Data are mean ± SD (n = 4). *p < 0.001 vs. HT29 cells. c. Representative flow cytometry histograms of MRP1 protein. Grey peaks: non immune
isotypic antibody. d. Cell surface MRP1 was determined by flow cytometry. Data are mean fluorescence intensity (MFI) ± SD (n = 3). *p < 0.02 vs. HT29
cells. e. Intracellular doxorubicin content, an index of MRP1 activity, measured by fluorimetry. Data are mean ± SD (n = 3). *p < 0.001 vs. HT29 cells
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between sensitive and resistant clones in vitro [7], HT29/
MDR cells displayed higher migration (Additional file 12),
indicating a higher aggressive phenotype. This may ex-
plain the faster growth of tumors derived from HT29/
MDR cells. Oxaliplatin treatment alone reduced tumor
growth and increased the percentage of apoptotic cells in
the HT29-derived tumors but not in the HT29/MDR
tumors, which were strongly positive for PERK and MRP1
(Fig. 6a-d).
Administration of doxycycline decreased HT29/MDR
tumor growth (Fig. 6a, b), reduced the percentage of cells
positive for PERK and MRP1 and increased the number of
cells positive for cleaved caspase 3 (Fig. 6c, d). The antitu-
mor effect of oxaliplatin against HT29/MDR tumors was
fully restored in doxycycline-treated animals, showing a
significant decrease in tumor growth, in line with that of
oxaliplatin-treated HT29 tumors (Fig. 6a, b), a decrease in
the expression of PERK and MRP1, an increase in intratu-
mor apoptosis (Fig. 6c, d).
Discussion
Chemotherapeutic agents act at least in part by trigger-
ing ER stress [3, 4]. We have recently demonstrated that
cells with an acquired resistance to chemotherapy are
also resistant to ER stress-triggered cell death [7]. Here
we demonstrated that also the inverse sequence of
events occurs in cancer cells: the progressive adaptation
of chemosensitive cells to ER stress inducers selects cells
that are resistant to multiple chemotherapeutic drugs.
The acquisition of this double-resistant phenotype, re-
gardless of the ER stress inducer used or the tumor type,
was paralleled by the up-regulation of MRP1.
The correlation between acute exposure to ER stress in-
ducers and MRP1 is matter of debate. For instance, thapsi-
gargin did not change MRP1 level in prostate cancer cells
[24], but increased MRP1 in colon and lung cancer [25].
Acute exposure to tunicamycin alters the glycosylation of
MRP1 and MRP4 and increases the resistance to oxaliplatin
in ovarian cancer cells, but under these conditions MRP4 is
Fig. 3 PERK expression in cells resistant to chemotherapy and to ER stress. a, b. Relative expression of 83 UPR genes in untreated HT29/Tun vs. HT29 cells
(a), and in untreated HT29/MDR vs. HT29 cells (b). The Volcano plots are representative of 4 independent experiments. The spots corresponding to
PERK are encircled. c. Immunoblots of the indicated proteins in extracts of untreated cells. β-tubulin was used as a loading control. The figure is
representative of 3 experiments with similar results. d. Nrf2 mRNA levels in extracts of untreated cells. Data are mean ± SD (n = 4). *p < 0.005
vs. HT29 cells. e. Immunoblot of Nrf2 in nuclear extracts of the indicated cells. TATA-box binding protein (TBP) served as a loading control. The figure is
representative of 3 experiments with similar results. f. Binding of Nrf2 to the ABCC1/MRP1 promoter (ABCC1 pro) as measured by ChIP. The figure is
representative of 3 experiments with similar results. Amplification of ABCC1 promoter from genomic DNA (input) was used as control of equal DNA
loading. No Ab: HT29/MDR DNA fragments were immunoprecipitated without the anti-Nrf2 antibody and used as a negative control
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apparently the prominent player in chemoresistance [26].
Acute exposure to brefeldin A prevents MRP1 transloca-
tion from Golgi apparatus to plasma-membrane [27]. Our
study differs from the previous ones because it was aimed
at selecting clones adapted to survive in prolonged condi-
tions of mild ER stress. This approach simulates the process
that occurs in solid tumors constantly facing several condi-
tions inducing ER stress, such as nutrient deprivation,
hypoxia, radiotherapy or chemotherapy [1–4].
By comparing of the expression of UPR-related genes
we noticed that PERK was the only gene significantly
up-regulated in both cells selected for chemoresistance
and cells selected for ER stress resistance. This analysis
led us to investigate whether the activation of PERK was
responsible for the resistance to either ER stress or
chemotherapy.
Depending on tumor type and activation kinetics, PERK
may promote cell death or survival [28, 29]. Such
Fig. 4 Role of the PERK/Nrf2 axis in MRP1 expression and activity. Human chemoresistant colon cancer HT29/MDR cells and ER stress-resistant clones
(HT29/Tg, HT29/Tun, HT29/Bfa) were stably and inducibly silenced for PERK (siPERK). Silencing was induced by doxycycline (doxy, 1 μg/mL, 72 h). HT29
cells were used as control of chemosensitive/ER stress-sensitive cells. a. Immunoblots of protein extracts from the indicated cells stably and inducibly
silenced for PERK (siPERK). β-tubulin was used as a loading control. The figure is representative of 3 experiments with similar results. b. Immunoblots of
Nrf2 in nuclear extracts of cells stably and inducibly silenced for PERK, or treated with PD98059 (10 μM, 72 h), which prevents Nrf2 nuclear translocation.
TBP was used as a loading control. The figure is a representative of 3 experiments with similar results. c. Total MRP1 mRNA in extracts of the indicated
cells. Data are mean ± SD (n = 4). *p < 0.001 for siPERK-treated cells vs. untreated HT29 cells; °p < 0.001 for siPERK + doxy-treated cells/PD98059-treated
cells, vs. the corresponding condition in siPERK – doxy cells. d. Cell surface MRP1 as measured by flow cytometry. Data are mean fluorescence intensity
(MFI) ± SD. (n = 3). *p < 0.002 for siPERK(− doxy)-treated cells vs. untreated HT29 cells; °p < 0.005 for siPERK(+ doxy)-treated cells and PD98059-treated
cells vs. the corresponding cell type in siPERK(−doxy) cells. e. Doxorubicin uptake in cells treated as above and measured by fluorimetry. Data are
mean ± SD (n = 3). *p < 0.001 for siPERK(− doxy)-cells vs. untreated HT29 cells; °p < 0.001 for siPERK(+ doxy)-treated cells and PD98059-treated cells
vs. the corresponding cell type in siPERK(−doxy) cells
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pleiotropism is reflected by the highly variable and tumor-
dependent prognostic role of PERK and Nrf2 in human
tumors: mutations in specific oncogenes or oncosuppres-
sor genes, factors related to the tumor micro-environment
and immune-system anti-tumor activity, different treat-
ments used in patients likely explain the great variability
linking PERK/Nrf2 expression and clinical outcome.
Contrasting findings have been reported also on the
role of PERK in response to anti-cancer treatments. For
instance, acute activation of PERK is required for colon
cancer cell death mediated by sulindac [30], mesalamine
derivatives [31] and histone deacetylase inhibitors [32],
suggesting a chemosensitizing role for PERK. In con-
trast, the prolonged activation of PERK and consequent
Fig. 5 Role of the PERK/Nrf2 axis in resistance to chemotherapy and to ER stress. Human chemoresistant colon cancer HT29/MDR cells and ER
stress-resistant clones (HT29/Tg, HT29/Tun, HT29/Bfa) were stably and inducibly silenced for PERK (siPERK). Silencing was induced by doxycycline
(doxy, 1 μg/mL, 72 h). HT29 cells were used as control of chemosensitive/ER stress-sensitive cells. a, b. Release of the necrosis marker HMGB1 to
culture media of the indicated cells following incubation in fresh medium (Ctrl), or in media containing: thapsigargin (Tg), tunicamycin (Tun),
brefeldin A (Bfa), oxaliplatin (oPt), 5-fluorouracil (5FU), doxorubicin (Dox), as indicated in Methods. Data are mean ± SD (n = 3). *p < 0.001 for
treated cells vs. Ctrl HT29 cells; °p < 0.001 for siPERK – doxy cells vs. HT29 cells treated with the same agent; #p < 0.05 for siPERK + doxy cells vs.
siPERK – doxy cells treated with the same agent. c, d. Viability of cells measured by Neutral red staining. Data are mean ± SD (n = 4). *p < 0.001
for treated cells vs. Ctrl HT29 cells; °p < 0.01 for siPERK – doxy cells vs. HT29 cells treated with the same agent; #p < 0.001 for siPERK + doxy cells vs.
siPERK – doxy cells treated with the same agent. e. Crystal violet staining of cells grown in 96-well plates and treated as in a and b. The
images are representatives of at least 5 microscopic fields showing similar cell density. Bar = 500 μM
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phosphorylation of EIF2α counteract the cytotoxic effects
of tumor necrosis factor-α (TNF-α) and bortezomib [33],
docosahexaenoic acid and TNF-related apoptosis inducing
ligand [34], thereby preventing the UPR-mediated cell
death. These findings are in line with our observations:
indeed, clones exhibiting constitutively active PERK were
more resistant to cell death triggered either by ER stress or
by chemotherapy. The constant challenge with ER stress
inducers selected clones with a constitutive up-regulation
of PERK and MRP1. Our finding that the PERK-induced
Nrf2 activation up-regulates MRP1 expression provides
the mechanism by which ER stress induces MRP1 and
subsequent MRP1-dependent chemoresistance.
The correlation between Nrf2 and chemoresistance is
well known, in particular in colon cancer, where Nrf2
even serves as a marker of chemoresistance [35, 36]. The
resistance to platinum-derivatives in Nrf2 expressing
cells is usually attributed to the simultaneous up-
regulation of antioxidant enzymes, phase II metabolizing
enzymes and drug efflux transporters, including MRP1
Fig. 6 The role of PERK in chemosensitivity in vivo. a. Tumor growth of HT29 and HT29/MDR, inducibly silenced for PERK, untreated (Ctrl) or
treated with oxaliplatin (oPt), as indicated in Methods. Data are mean ± SD (15 mice/group). *p < 0.01 for HT29 oPt vs. HT29 Ctrl group; °p < 0.005
for HT29/MDR Ctrl – doxy vs. HT29 Ctrl, HT29/MDR oPt – doxy vs. HT29 oPt group; #p < 0.005 for HT29/MDR Ctrl + doxy vs. HT29/MDR Ctrl – doxy,
HT29/MDR oPt + doxy vs. HT29/MDR oPt – doxy. b. Photographs of representative tumors of each group. c Sections of tumors from each group
of animals stained with hematoxylin and eosin (HE) or with the indicated antibodies. Nuclei were counter-stained with hematoxylin. Bar = 10 μm.
The photographs are representative of sections from 5 tumors. d. Immunostaining quantification. Percentage of PERK, MRP1 and cleaved caspase
3-positive cells was determined in sections from 5 animals of each group (91–109 cells/field), using Photoshop program. *p < 0.002 for HT29/MDR
Ctrl – doxy vs HT29 Ctrl, HT29/MDR oPt – doxy vs HT29 oPt, °p < 0.02 for HT29/MDR Ctrl + doxy vs HT29/MDR Ctrl – doxy, HT29/MDR oPt + doxy
vs HT29/MDR oPt – doxy
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[37, 38]. Both antioxidant enzymes and MRP1 were in-
deed up-regulated in ER stress-resistant cancer cells,
explaining the refractoriness of these clones to oxalipla-
tin and cisplatin. The strong up-regulation of MRP1
may explain the simultaneous resistance of ER stress-
resistant clones to 5-fluorouracil and doxorubicin, two
other substrates of MRP1.
Of note, we also detected a similar activation of PERK/
Nrf2/MRP1 axis in the HT29/MDR clone, i.e. a clone with
an acquired resistance to chemotherapy and ER stress [7].
It is known that stepwise selection with doxorubicin led to
increased Nrf2 expression in ovary cancer cells [39]. It is
likely that the same process occurred in HT29/MDR cells,
selected with increasing concentration of doxorubicin
[20]. Indeed, the analysis of upstream and downstream
targets of PERK and Nrf2 in PERK-silenced and Nrf2-
inhibited cells revealed a strong parallelism between
chemoresistant and ER stress-resistant cells: in both popu-
lations PERK and its downstream targets are up-regulated,
and PERK controls Nrf2 expression. The PERK/Nrf2 axis
in turn finely controls the expression of specific gene sets,
involved in the protection from oxidant and xenobiotic
agents like chemotherapeutic drugs. We thus propose that
PERK/Nrf2-controlled genes, including MRP1, may be
critical for the acquisition and maintenance of the dual
resistance to chemotherapy and ER stress.
Disrupting PERK/Nrf2 axis re-sensitized both ER
stress-resistant clones and chemoresistant clones to ER
stress-triggered and chemotherapy-triggered cell death,
overcoming the double- and cross-resistant phenotype.
In preclinical models of colon cancer, PERK-inhibition
made ER stress-resistant/MDR tumors as responsive to
oxaliplatin as ER stress-sensitive/chemosensitive tumors:
this chemosensitizing effects was likely due to the de-
creased expression of MRP1 that restored the pro-
apoptotic effects of oxaliplatin in resistant tumors.
Conclusions
We demonstrated for the first time that adaptation to
ER stress leads to the acquisition of a MDR phenotype
in different tumor types, as a consequence of the consti-
tutive activation of PERK/Nrf2/MRP1 axis. Disrupting
this axis may overcome MRP1-dependent chemoresis-
tance, opening new perspectives for the treatment of
aggressive and resistant solid tumors.
Additional files
Additional file 1: IC50 (μM) of chemotherapeutic agents and ER stress
inducers in HT29 and HT29/MDR cells. Data are mean ± SD (n = 3).
*p < 0.02 for HT29/MDR vs. HT29 cells. (XLSX 12 kb)
Additional file 2: Primers used in qRT-PCR experiments. (XLSX 12 kb)
Additional file 3: Effect of oxaliplatin in 3D-cultures of colon cancer
cells. Human chemosensitive HT29 cells, chemoresistant HT29/MDR cells
and ER stress-resistant HT29/Tun cells were cultured 7 days embedded in
Biomimesys™ matrix to generate 3D-systems. Medium was replaced with
fresh medium (Ctrl) or with medium containing 10 μM oxaliplatin (oPt) for
48 h, then cells were analysed by contrast phase microscope. The images
are representative of 3 independent experiments. Bar = 50 μM. (TIF 1680 kb)
Additional file 4: Effects of chemotherapeutic drugs in human
chemosensitive breast cancer cells with acquired resistance to ER stress. a.
Release of the necrosis marker HMGB1 to culture media of human
chemosensitive breast cancer MCF7 cells and the ER stress-resistant clone
MCF7/Tun, grown in fresh medium (Ctrl) or in media containing: thapsigargin
(Tg), tunicamycin (Tun), brefeldin A (Bfa), doxorubicin (Dox), cisplatin (Pt), as
indicated in Methods. Data are mean ± SD (n= 3). *p< 0.001 vs MCF7 Ctrl cells;
°p< 0.001 for MCF7/Tun treated cells vs MCF7 treated cells. b. Viability
of cells measured by Neutral red staining. Data are mean ± SD (n= 3).
*p< 0.05 vs MCF7 Ctrl cells; °p< 0.02 for MCF7/Tun treated cells vs MCF7
treated cells. c. Whole cell lysates were analyzed for the expression of MRP1.
β-tubulin expression was used as control of equal protein loading. The
figure is representative of 3 experiments with similar results. d. MRP1 mRNA
levels were measured by qRT-PCR. Data are mean ± SD (n= 3). *p< 0.01 vs
MCF7 cells. e. MRP1 protein on cell surface was measured by flow cytometry.
Left panel: data are presented as mean fluorescence intensity (MFI) ± SD
(n= 3). *p< 0.02 vs MCF7 cells. Right panel: representative flow cytometry
histograms. Grey peak: non immune isotypic antibody. f. Intracellular
doxorubicin content, an index of MRP1 activity, measured by fluorimetry.
Data are mean ± SD (n= 3). *p< 0.005 vs MCF7 cells. (TIF 1434 kb)
Additional file 5: Effects of chemotherapeutic drugs in human
chemosensitive osteosarcoma cells with acquired resistance to ER stress.
a. Release of the necrosis marker HMGB1 to culture media of human
chemosensitive osteosarcoma U-2OS cells and the ER stress-resistant
clone U-2OS /Tun, grown in fresh medium (Ctrl) or in media containing:
thapsigargin (Tg), tunicamycin (Tun), brefeldin A (Bfa), doxorubicin (Dox),
cisplatin (Pt), as indicated in Methods. Data are mean ± SD (n = 3).
*p < 0.005 vs U-2OS Ctrl cells; °p < 0.005 for U-2OS/Tun treated cells vs
U-2OS treated cells. b. Viability of cells measured by Neutral red staining.
Data are mean ± SD (n = 3). *p < 0.02 vs U-2OS Ctrl cells; °p < 0.05 for U-
2OS/Tun treated cells vs U-2OS treated cells. c. Whole cell lysates were
analyzed for the expression of MRP1. β-tubulin expression was used as
control of equal protein loading. The figure is representative of 3
experiments with similar results. d. MRP1 mRNA levels were measured by
qRT-PCR. Data are mean ± SD (n = 3). *p < 0.005 vs U-2OS cells. e. MRP1
protein on cell surface was measured by flow cytometry. Left panel: data
are presented as mean fluorescence intensity (MFI) ± SD (n = 3). *p < 0.02
vs U-2OS cells. Right panel: representative flow cytometry histograms.
Grey peak: non immune isotypic antibody. f. Intracellular doxorubicin
content, an index of MRP1 activity, measured by fluorimetry. Data are
mean ± SD (n = 3). *p < 0.05 vs U-2OS cells. (TIF 1533 kb)
Additional file 6: Expression of genes involved in the UPR in HT29,
HT29/Tun and HT29/MDR cells. ERAD: ER-associated degradation; UPR:
unfolded protein response; ERQC: ER-quality control. Fold-Change
(2^(− Delta Delta Ct)) is the normalized gene expression (2^(− Delta Ct))
in HT29/Tun or HT29/MDR cells, divided the normalized gene expression
(2^(− Delta Ct)) in HT29 cells (n = 4), where Ct is the threshold cycle in
qRT-PCR. Fold-change values greater than 1 indicate up-regulation, fold-
change values less than 1 indicate down-regulation. The p values are
calculated based on a Student’s t-test of the replicate 2^(− Delta Ct)
values for each gene. p < 0.05 was considered significant. Genes
significantly up- or down-regulated more than 2-fold either in HT29/Tun
or HT29/MDR cells are in bold characters. (XLSX 16 kb)
Additional file 7: MRP1 expression on cell surface of sensitive and
resistant colon cancer cells upon PERK/Nrf2 inhibition. a, b. Representative
flow cytometry histograms of MRP1 protein in human chemoresistant colon
cancer HT29/MDR cells and ER stress-resistant clones (HT29/Tg, HT29/Tun,
HT29/Bfa), stably and inducibly transduced with a silencing vector for PERK,
or treated with PD98059 (10 μM, 72 h), which blocks Nrf2
nuclear translocation. HT29 were included as control of chemosensitive/ER
stress-sensitive cells. Grey peaks: non immune isotypic antibody. (TIF 1205 kb)
Additional file 8: Expression of PERK- and Nrf2-upstream and
downstream genes in chemoresistant and ER stress-resistant cells. a.
Schematic representation of upstream and downstream targets of PERK
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and Nrf2. Blue box: genes upstream PERK; red boxes: genes downstream
PERK; orange boxes: genes upstream Nrf2; green boxes: genes downstream
Nrf2. b. Relative expression, indicated in a colorimetric scale, of the indicated
PERK- and Nrf2-upstream and downstream genes, in HT29/MDR and HT29/
Tun cells, grown un fresh medium (Ctrl), transduced with a silencing vector
for PERK, or treated with PD98059 (PD; 10 μM, 72 h), measured by RT-PCR.
The expression of each gene in HT29 cells, used as internal control, was
considered equal to 1. Data are mean ± SD (n = 4). *p < 0.05 for untreated
(Ctrl) HT29/MDR or HT29/Tun cells vs. HT29 cells; °p < 0.05 for significantly
reduced genes in siPERK- and PD-treated cells vs. respective untreated (Ctrl)
HT29/MDR or HT29/Tun cells. GRP78: glucose-regulated protein 78; EIF2S1:
eukaryotic translation initiation factor 2 subunit 1; ATF4: activating
transcription factor 4; GSK3β: glycogen synthase kinase 3β; JNK1: c-
Jun N-terminal kinase 1; MAPK1: mitogen activated kinase 1; PI3KCD:
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit δ;
PRKCA: protein kinase Cα; NFKB: nuclear factor-kB; GSR: glutathione-
disulfide reductase; G6PD: glucose-6-phosphate dehydrogenase;
TXNRD1: thioredoxin reductase 1; SOD1: superoxide dismutase 1;
HMOX1: heme oxygenase 1; NQO1: NAD(P)H quinone dehydrogenase
1; STIP1: stress induced phosphoprotein 1. (TIF 836 kb)
Additional file 9: Nrf2 inhibition reverses the resistance to chemotherapy
and ER stress. Human chemoresistant colon cancer HT29/MDR cells and ER
stress-resistant clones (HT29/Tg, HT29/Tun, HT29/Bfa) were grown in the
absence or in the presence of PD98059 (10 μM, 72 h), which blocks Nrf2
nuclear translocation. a, b. Release of the necrosis marker HMGB1 to culture
media of the indicated cells following incubation in fresh medium (Ctrl), or
in media containing: thapsigargin (Tg), tunicamycin (Tun), brefeldin A (Bfa),
oxaliplatin (oPt), 5-fluorouracil (5FU), doxorubicin (Dox), as indicated
in Methods. Data are mean ± SD (n = 3). *p < 0.001 vs HT29 Ctrl cells;
°p < 0.001 for HT29/MDR, HT29/Tg, HT29/Tun, HT29/Bfa vs HT29 cells;
#p < 0.001 for PD98059-treated cells vs PD98059-untreated cells. c, d.
Viability of cells measured by Neutral red staining. *p < 0.005 vs HT29
Ctrl cells; °p < 0.01 for HT29/MDR, HT29/Tg, HT29/Tun, HT29/Bfa vs
HT29 cells; #p < 0.02 for PD98059-treated cells vs PD98059-untreated
cells. (TIF 3494 kb)
Additional file 10: Correlation between PERK or NRF2 expression and
patient clinical outcome in different tumors. Patient overall survival was
calculated by Cox's proportional hazard model and Kaplan-Meier method
using the GSEA software. Z score: correlation score between gene
expression and survival. FDR: false discovery rate. ACC: adrenocortical
carcinoma; BRCA: breast invasive carcinoma; BLCA: bladder urothelial
carcinoma; CESC: cervical squamous cell carcinoma and endocervical
adenocarcinoma; CHOL: cholangiocarcinoma; COAD: colon adenocarcinoma;
COADREAD: colorectal adenocarcinoma; DLBC: diffuse large B-cell lymphoma;
GBM: glioblastoma multiforme; HNSC: head and neck squamous cell
carcinoma; KICH: chromophobe renal cell carcinoma; KIRC: kidney renal clear
cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LGG: lower grade
glioma; LIHC: liver hepatocellular carcinoma; LUAD: lung adenocarcinoma;
LUSC: lung squamous cell carcinoma; MESO: mesothelioma; OV: ovarian
serous cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PCPG:
pheochromocytoma and paraganglioma; PRAD: prostate adenocarcinoma;
READ: rectum adenocarcinoma; SARC: sarcoma; SKCM: skin cutaneous
melanoma; TGCT: testicular germ cell tumor; THCA: thyroid carcinoma;
THYM: thymoma; UCEC: uterine corpus endometrial carcinoma; UCS: uterine
carcinosacoma; UVM: uveal melanoma. Significant p values are in bold
characters. (XLSX 17 kb)
Additional file 11: Tumor growth in mice bearing HT29 and HT29/MDR
tumors. Tumor volume (reported in mm3) of HT29 and HT29/MDR,
inducibly silenced for PERK, untreated (Ctrl) or treated with oxaliplatin
(oPt), as indicated in Methods and in the main Figure 6, at different time
points for each animal. (XLSX 24 kb)
Additional file 12: Migration of sensitive and resistant colon cancer
cells. Migration ability of HT29, HT29/MDR and HT29/Tun cells was
evaluated as capacity to close the wound over a period of 24 h.
a. Representative images of 1 out of 3 experiments. Bar: 200 μm.
b. Quantification of migration rate. Data are mean ± SD (n = 3).
*p < 0.002 vs HT29 cells; °p < 0.001 vs HT29/MDR cells.
(TIF 2275 kb)
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Additional file 1 
Drug Transporter HT29 HT29/MDR 
doxorubicin Pgp,  MRP1, MRP2, MRP3, BCRP 6.12 + 0.11 12.73 + 0.24 * 
vinblastine Pgp, MRP1, MRP2 4.01 + 0.25 10.06 + 0.62 * 
etoposide Pgp, MRP1, MRP2, MRP3 1.03 + 0.11 10.12 + 0.71 * 
irinotecan Pgp, MRP1, MRP2 6.11 + 0.52 38.23 + 7.81 * 
cisplatin MRP1, MRP2, MRP4 11.24 + 1.85 44.67 + 5.84 * 
oxaliplatin MRP1, MRP4 6.12 + 0.79 19.92 + 1.23 * 
5-fluorouracile MRP1, MRP3, MRP4, MRP5 6.72 + 0.091 17.12 + 0.56 * 
methotrexate Pgp, MRP1, MRP2, MRP3, MRP4, BCRP 2.55 + 0.41 9.18 + 1.03 * 
pemetrexed MRP5 0.82 + 0.12 8.77 + 0.34 * 
gemcitabine MRP5 0.13 + 0.6 0.81 + 0.12 * 
mitoxantrone Pgp, MRP1, BCRP 5.13 + 0.27 10.23 + 0.37 * 
thapsigargin - 16.21 + 2.14 49.26 + 11.24 * 
tunicamycin - 1.86 + 0.12 5.04 + 0.19 * 
brefeldin A -  1.25 + 0.36 52.85 + 9.88 * 
  
Additional file 2 
Gene Forward primer (5’-> 3’) Reverse primer (5’-> 3’) 
GRP78 GGTGCAGCAGGACATCAAGTT CCCACCTCCAATATCAACTTGA 
PERK TCTTGGTCCCACTGGAAGAG AAAGCAGTGGGATTTGGATG 
EIF2S1 TACTTTTTCTCCATTGCCCC GGTGAATGGACCACCACATT 
ATF4 GAAGGTCATCTGGCATGGTT AGTCCCTCCAACAACAGCAA 
GADD34 TTTTGGCAACCAGAACCG GGAGATAGAAGTTGTGGGCG 
NRF2 TCTTGCCTCCAAAGTATGTCAA ACACGGTCCACAGCTCATC 
GSR ACCCTCACAACTTGGAAAGC ACAAGCTGGGTGGCACTT 
G6PD AGGTGTTTTCGGGCAGAAG GCCTTCCATCAGTCGGATAC 
TXRND1 TCAGGGCCGTTCATTTTTAG GATCTGCCCGTTGTGTTTG 
SOD1 ACTGGTGGTCCATGAAAAAGC AACGACTTCCAGCGTTTCCT 
HMOX1 CTCAAACCTCCAAAAGCC TCAAAAACCACCCCAACCC 
NQO1 CTCGCCTCATGCGTTTTTG CCCCTAATCTGACCTCGTTCAT 
STIP1 GCAGCTACGAAACAAGCCTTCT GACGCTGAGAGTGGTCATGATC 
NFKB GAAGGAATCGTACCGGGAACA  CTCAGAGGGCCTTGTGACAGTAA 
MAPK1 TCTGGCAGGCAGGCAGGCAAT TGACCGGGAGGAGGAAGGAAGA 
GSK3β GGAACTCCAACAAGGGAGCA TTCGGGGTCGGAAGACCTTA 
JNK1 TGGACTTGGAGGAGAGAACC ACGATGATGATGGATGCTGA 
PI3KCD AATGAAACCCCTGTGGATCA TCTGCAGAGTCAGCATG 
PRKCA GCGTCTCAGGACGTGGCCAAC TTTCCCAAACCCCCAGATGAAGTCG 
MRP1 TCCACCAGAAGGTGATCCTC GTTTCTCAGATCGCTCACCC 
S14 CGAGGCTGATGACCTGTTCT GCCCTCTCCCACTCTCTCTT 
 
Additional file 3 
  
Additional file 4 
 
  
Additional file 5 
 
  
Additional file 6 
Ref Seq Gene name Biological function 
Fold change 
HT29/Tun  
vs HT29 cells 
p value 
Fold change 
HT29/MDR 
vs HT29 cells 
p value 
NM_001144 AMFR ERAD; cholesterol homeostasis 0.18 ns 1.16 ns 
NM_024866 ADM2 Protein synthesis 0.02 ns 0.76 ns 
NM_183356 ASNS Protein synthesis 0.31 0.001 0.30 0.001 
NM_001675 ATF4 UPR 4.95 0.001 1.04 ns 
NM_007348 ATF6 UPR 1.33 ns 1.12 ns 
NM_004381 ATF6B UPR 0.13 0.001 1.20 ns 
NM_004993 ATXN3 ERQC/ERAD 5.2 ns 0.79 ns 
NM_004324 BAX Cell death 1.31 ns 1.53 ns 
NM_032621 BEX2 Cell death 0.03 ns 0.88 ns 
NM_004343 CALR ERQC 5.53 0.001 0.94 ns 
NM_001746 CANX ERQC 3.39 0.001 1.33 ns 
NM_006430 CCT4 ERQC 0.47 0.001 0.49 0.001 
NM_005194 CEBPB Cell death or survival 97.59 0.001 0.88 ns 
NM_006368 CREB3 Cell death or survival 2.61 ns 0.94 ns 
NM_032607 CREB3L3 UPR 0.06 ns 1.16 ns 
NM_004083 DDIT3 Cell death 0.88 ns 0.41 0.001 
NM_024295 DERL1 ERAD 2.11 0.01 1.38 ns 
NM_012328 DNAJB9 Cell survival 2.1 0.01 0.23 0.001 
NM_018981 DNAJC10 ERAD 0.61 0.05 0.69 ns 
NM_006260 DNAJC3 ERQC; UPR 0.72 ns 0.47 0.02 
NM_014674 EDEM1 ERAD 0.95 ns 0.82 ns 
NM_032025 EIF2A UPR 3.63 0.001 1.95 ns 
NM_004836 EIF2AK3/PERK UPR; cell death 15.37 0.02 17.27 0.05 
NM_001433 ERN1 Cell death 0.92 ns 1.01 ns 
NM_033266 ERN2 Cell death 0.43 ns 1.88 ns 
NM_014584 ERO1L ERQC; cell death 0.69 ns 0.64 ns 
NM_019891 ERO1LB Cell death 0.22 ns 0.88 ns 
NM_015051 ERP44 ERQC 0.42 0.001 0.47 0.001 
NM_018438 FBXO6 ERAD 0.05 ns 0.88 ns 
NM_198334 GANAB ERQC 4.68 0.005 0.79 ns 
NM_198141 GANC ERQC 1.55 ns 0.88 ns 
NM_016095 GINS2 Cell cycle 0.02 ns 0.91 ns 
NM_014685 HERPUD1 ERQC; ERAD 2.23 0.02 2.54 ns 
NM_005346 HSPA1B ERQC 4.34 0.005 1.20 ns 
NM_021979 HSPA2 ERQC 0.21 ns 0.42 ns 
NM_002154 HSPA4 ERQC 0.67 ns 0.52 ns 
NM_014278 HSPA4L ERQC 0.86 ns 0.28 0.001 
NM_005347 HSPA5 ERQC; UPR 4.17 0.001 0.21 0.05 
NM_006644 HSPH1 ERQC; UPR 0.3 0.001 0.10 0.001 
NM_013247 HTRA2 Cell death 2.99 ns 1.82 ns 
NM_153692 HTRA4 ERQC 0.01 ns 0.45 ns 
NM_031479 INHBE Cell cycle 0.16 ns 0.88 ns 
NM_016133 INSIG2 ERAD; cholesterol homeostasis 4.5 0.001 0.82 ns 
NM_014407 KCNMB3 Calcium flux 0.29 0.02 0.54 0.05 
NM_006010 MANF Cell survival 0.62 0.02 1.01 ns 
NM_002750 MAPK8 Cell death or survival 1.06 ns 1.24 ns 
NM_002752 MAPK9 Cell death 0.27 0.005 0.79 ns 
NM_003791 MBTPS1 Cholesterol homeostasis 1.84 ns 0.82 ns 
NM_015884 MBTPS2 Cholesterol homeostasis 1.97 ns 0.41 ns 
NM_005914 MCM4 Cell cycle 0.04 ns 0.07 ns 
NM_017921 NPLOC4 ERAD 6.85 0.01 0.82 ns 
NM_006184 NUCB1 UPR 1.98 ns 1.16 ns 
NM_006812 OS9 ERAD 6.61 0.01 1.12 ns 
NM_182649 PCNA Cell cycle 0.65 0.05 0.56 0.01 
NM_005313 PDIA3 ERQC 0.88 ns 1.95 0.02 
NM_002624 PFDN5 ERQC 0.47 0.001 0.45 0.002 
NM_021130 PPIA ERQC 30.92 0.001 0.40 0.005 
NM_014330 PPP1R15A Cell survival 6.16 0.005 0.79 ns 
NM_002743 PRKCSH ERQC 0.95 ns 1.75 0.05 
NM_006913 RNF5 ERAD 0.01 0.002 1.08 ns 
NM_002950 RPN1 ERQC 4.21 0.005 1.75 ns 
NM_001034 RRM2 Cell cycle 1.77 ns 1.20 ns 
NM_012235 SCAP Cholesterol homeostasis 0.68 ns 0.66 ns 
NM_003262 SEC62 ERQC 6.82 0.001 0.50 0.05 
NM_007214 SEC63 ERQC 0.28 ns 0.41 ns 
NM_005065 SEL1L ERQC 0.89 ns 0.71 ns 
NM_203472 SELS ERAD 0.01 0.002 1.33 ns 
NM_014445 SERP1 ERQC 3.63 0.001 0.49 ns 
NM_022464 SIL1 ERQC 0.36 ns 0.41 ns 
NM_005835 SLC17A2 Phosphate transport 0.02 ns 0.88 ns 
NM_004176 SREBF1 Cholesterol homeostasis 0.80 ns 0.88 ns 
NM_172230 SYVN1 ERQC; cell survival 0.49 ns 0.79 ns 
NM_030752 TCP1 ERQC 1.21 ns 0.88 ns 
NM_000113 TOR1A ERQC 0.89 ns 0.62 0.01 
NM_021158 TRIB3 Cell death 9.66 0.002 1.16 ns 
NM_001071 TYMS Cell cycle 2.11 0.05 1.16 ns 
NM_182688 UBE2G2 ERAD 0.95 ns 0.97 ns 
NM_014607 UBXN4 ERAD 3.19 0.005 1.08 ns 
NM_005659 UFD1L ERAD 0.41 0.005 0.76 ns 
NM_020120 UGGT1 ERQC 0.37 0.01 0.79 ns 
NM_013282 UHRF1 Cell cycle 0.68 ns 0.85 ns 
NM_005151 USP14 ERAD 0.38 0.001 0.91 ns 
NM_007126 VCP ERAD 1.49 ns 0.91 ns 
NM_005080 XBP1 UPR 1.38 ns 1.28 ns 
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Additional file 10 
PERK Cox analysis Kaplan Maier analysis 
Cancer Z score P value FDR Bonf Z score P value FDR Bonf 
ACC 0.278136 0.780908 0.911764 1 0.01913 0.984737 0.984737 1 
BRCA 2.828704 0.004674 0.074779 0.149558 2.462023 0.013816 0.360671 0.442099 
BLCA -2.2441 0.024826 0.160596 0.794441 -1.92356 0.054409 0.435275 1 
CESC 0.105952 0.915621 0.971575 1 0.029184 0.976718 0.984737 1 
CHOL -0.53546 0.592333 0.83065 1 -1.02126 0.307133 0.702018 1 
COAD -1.38881 0.164891 0.376893 1 -0.67457 0.49995 0.764201 1 
COADREAD -2.10685 0.03513 0.160596 1 -1.65306 0.098319 0.629239 1 
DLBC 0.488855 0.624944 0.833259 1 0.831673 0.405593 0.764201 1 
GBM -1.62135 0.104942 0.305285 1 -2.07034 0.03842 0.409816 1 
HNSC -1.01405 0.310558 0.621117 1 -0.63506 0.525388 0.764201 1 
KICH -1.53448 0.124913 0.308976 1 -1.14547 0.252016 0.686005 1 
KIRC -0.21947 0.826286 0.911764 1 0.652533 0.514058 0.764201 1 
KIRP 1.760034 0.078402 0.250886 1 1.083268 0.278689 0.686005 1 
LGG 4.649562 3.33E-06 0.000106 0.000106 2.28111 0.022542 0.360671 0.721343 
LIHC -0.04139 0.966984 0.971575 1 -0.17992 0.857215 0.945893 1 
LUAD -2.41796 0.015608 0.160596 0.499454 -0.75502 0.450235 0.764201 1 
LUSC -0.831 0.405971 0.721726 1 -0.42283 0.672421 0.807565 1 
MESO -0.52887 0.596897 0.83065 1 1.35034 0.176907 0.686005 1 
OV 0.590941 0.55456 0.83065 1 1.087759 0.276702 0.686005 1 
PAAD 0.528677 0.59703 0.83065 1 0.410577 0.681383 0.807565 1 
PCPG 0.881311 0.378149 0.711811 1 0.101699 0.918996 0.980262 1 
PRAD 1.115828 0.264496 0.564257 1 0.715212 0.474478 0.764201 1 
READ -1.78093 0.074923 0.250886 1 -1.27514 0.202261 0.686005 1 
SARC 0.310916 0.755865 0.911764 1 0.686124 0.492635 0.764201 1 
SKCM 0.035633 0.971575 0.971575 1 0.541657 0.588055 0.784073 1 
TGCT 0.246933 0.80496 0.911764 1 0.572365 0.567074 0.784073 1 
THCA 1.532005 0.125521 0.308976 1 1.136359 0.255806 0.686005 1 
THYM -2.16833 0.030133 0.160596 0.964268 -1.12468 0.260725 0.686005 1 
UCEC 0.301223 0.763244 0.911764 1 0.469835 0.638473 0.807565 1 
UCS -0.63087 0.528128 0.83065 1 -0.24051 0.809931 0.925636 1 
UVM 1.981637 0.04752 0.190079 1 1.412499 0.157803 0.686005 1 
 
  
NRF2 Cox analysis Kaplan Maier analysis 
Cancer Z score P value FDR Bonf Z score P value FDR Bonf 
ACC 0.786322 0.431679 0.790614 1 -0.2401 0.81025 0.918393 1 
BRCA 0.038224 0.969509 0.969509 1 -0.17511 0.860994 0.918393 1 
BLCA -2.01463 0.043944 0.234368 1 -1.81675 0.069255 0.369358 1 
CESC -0.80695 0.419698 0.790614 1 -0.96133 0.336386 0.740407 1 
CHOL -0.70512 0.480739 0.809665 1 -0.44288 0.657853 0.915274 1 
COAD 1.152399 0.249157 0.790614 1 2.384445 0.017105 0.136839 0.547356 
COADREAD 0.620265 0.535084 0.843862 1 0.622063 0.5339 0.839955 1 
DLBC 0.057778 0.953926 0.969509 1 0.21419 0.830399 0.918393 1 
GBM 0.451882 0.651354 0.843862 1 0.315005 0.752758 0.918393 1 
HNSC 0.423316 0.672065 0.843862 1 -0.57378 0.566113 0.839955 1 
KICH -2.61786 0.008848 0.093788 0.283149 -1.40917 0.158785 0.63514 1 
KIRC -1.88988 0.058774 0.268683 1 -2.38934 0.016879 0.136839 0.540116 
KIRP 0.846569 0.397236 0.790614 1 0.940296 0.347066 0.740407 1 
LGG 5.181899 2.2E-07 7.03E-06 7.03E-06 4.181535 2.9E-05 0.000927 0.000927 
LIHC 0.900663 0.367767 0.790614 1 -0.03833 0.969427 0.969427 1 
LUAD 0.334 0.73838 0.843862 1 -0.09992 0.920408 0.950099 1 
LUSC -0.99231 0.321049 0.790614 1 -1.84481 0.065066 0.369358 1 
MESO -3.13421 0.001723 0.027571 0.055142 -3.3028 0.000957 0.015316 0.030632 
OV -0.5351 0.592582 0.843862 1 -0.55709 0.577469 0.839955 1 
PAAD 2.520361 0.011723 0.093788 0.37515 -0.19116 0.848399 0.918393 1 
PCPG 0.916985 0.359151 0.790614 1 0.702402 0.482428 0.839955 1 
PRAD 0.461007 0.644794 0.843862 1 -0.89152 0.372648 0.745296 1 
READ -0.82841 0.407438 0.790614 1 -1.44047 0.149735 0.63514 1 
SARC -2.41358 0.015797 0.101099 0.505493 -1.10572 0.268849 0.716931 1 
SKCM 0.764247 0.44472 0.790614 1 1.319555 0.186984 0.664831 1 
TGCT 0.358824 0.719727 0.843862 1 0.597067 0.550463 0.839955 1 
THCA 0.336925 0.736174 0.843862 1 -0.18525 0.85303 0.918393 1 
THYM 0.171054 0.864181 0.921794 1 0.258771 0.795812 0.918393 1 
UCEC 0.491171 0.623305 0.843862 1 1.127203 0.259657 0.716931 1 
UCS 1.667592 0.095397 0.339189 1 0.953783 0.340194 0.740407 1 
UVM 1.757199 0.078884 0.315536 1 1.22559 0.220353 0.705129 1 
 
  
Additional file 11 
Group: HT29 Ctrl 
        
day 0 3 6 9 12 15 18 21 
mouse #1 95 329 552 826 1543 1892 2012 2234 
mouse #2 94 259 489 571 1278 1653 2210 2612 
mouse #3 110 456 672 1192 1572 1792 2673 2873 
mouse #4 113 501 792 849 1328 1562 1893 2098 
mouse #5 119 428 681 876 1291 1872 2091 2152 
mouse #6 90 289 362 624 1502 1936 2183 2312 
mouse #7 98 378 402 1192 1567 1921 2011 2267 
mouse #8 89 389 451 1109 1678 1932 2027 2178 
mouse #9 93 299 411 1193 1620 1973 2173 2271 
mouse #10 97 409 674 743 1381 1918 1981 2011 
mouse #11 91 390 629 791 1361 1723 1983 2091 
mouse #12 108 410 791 1192 1379 1645 1834 2139 
mouse #13 92 209 630 723 1367 1564 1801 2261 
mouse #14 98 201 679 802 1432 1659 1672 2190 
mouse #15 113 307 792 1045 1589 1792 1919 2188 
HT29 oPt 
        
day 0 3 6 9 12 15 18 21 
mouse #1 88 209 452 534 721 910 1032 1342 
mouse #2 132 481 681 882 902 1281 1452 1421 
mouse #3 123 339 729 821 1192 1329 1729 1982 
mouse #4 87 198 345 562 673 874 1088 1271 
mouse #5 92 191 381 508 691 1012 1562 1623 
mouse #6 93 184 362 663 832 983 1043 1452 
mouse #7 108 383 693 721 911 1284 1623 1782 
mouse #8 86 101 234 362 672 892 1182 1229 
mouse #9 128 202 271 302 783 934 1472 1562 
mouse #10 117 234 371 439 547 672 1029 1314 
mouse #11 83 178 391 431 802 993 1221 1372 
mouse #12 89 156 378 463 582 632 822 1235 
mouse #13 103 415 772 891 1034 1284 1293 1372 
mouse #14 83 209 381 409 582 783 923 1242 
mouse #15 89 291 362 427 530 924 992 1119 
 
  
HT29/MDR (- doxy)  Ctrl 
        
day 0 3 6 9 12 15 18 21 
mouse #1 117 502 982 1321 1872 2761 3381 3192 
mouse #2 81 581 1212 1452 2082 3261 3214 3552 
mouse #3 85 572 902 1192 1823 2451 2763 3976 
mouse #4 92 521 942 1129 1956 2212 3092 3232 
mouse #5 118 591 1182 1362 1892 2782 3278 3281 
mouse #6 111 589 1021 1282 1889 2217 2981 2766 
mouse #7 89 601 1192 1620 1992 2918 3672 4292 
mouse #8 81 672 1212 1521 1921 2034 2772 2832 
mouse #9 83 523 932 1361 2112 2671 3324 3181 
mouse #10 81 498 927 1244 1782 2116 2672 3252 
mouse #11 119 513 1002 1281 1823 2451 3187 3682 
mouse #12 118 571 1023 1672 2192 2715 3391 3662 
mouse #13 92 601 1182 1521 2188 2654 2579 3897 
mouse #14 119 621 1152 1562 2091 2312 3271 3356 
mouse #15 118 472 982 1821 2118 2978 3283 3688 
HT29/MDR (- doxy) oPt 
        
day 0 3 6 9 12 15 18 21 
mouse #1 92 433 905 1452 1882 2214 3242 3452 
mouse #2 111 541 982 1231 1772 2632 3761 4201 
mouse #3 92 452 892 1298 1623 2244 2812 3256 
mouse #4 82 398 821 1352 1882 2281 3092 3422 
mouse #5 114 401 991 1421 2048 2783 3505 3982 
mouse #6 112 445 778 1231 2044 2821 3492 3602 
mouse #7 82 448 892 1324 1988 2201 2781 3022 
mouse #8 93 612 882 1621 1924 2024 2281 2662 
mouse #9 121 523 801 1123 1824 2161 2541 2882 
mouse #10 88 447 1119 1241 1872 2834 3422 3621 
mouse #11 113 501 982 1189 1884 2271 2812 3212 
mouse #12 118 443 1023 1423 1982 2291 2866 3092 
mouse #13 115 421 889 1421 2281 2681 2872 3286 
mouse #14 88 402 882 1134 1872 2012 2888 2928 
mouse #15 83 298 698 844 1562 1662 2432 2678 
 
  
HT29/MDR (+ doxy) Ctrl 
        
day 0 3 6 9 12 15 18 21 
mouse #1 102 389 792 1281 1520 1892 2671 3068 
mouse #2 81 402 822 1192 1481 1998 2821 2809 
mouse #3 88 321 689 982 1392 1872 2281 2872 
mouse #4 92 420 702 1092 1482 1983 1982 2672 
mouse #5 122 381 789 998 1672 2221 2661 2708 
mouse #6 108 340 723 983 1662 2289 2401 2801 
mouse #7 119 309 788 1092 1789 2088 2019 2656 
mouse #8 88 349 621 923 1478 2002 2281 2451 
mouse #9 118 322 602 1251 1623 1778 1892 2281 
mouse #10 82 229 891 1267 1472 1726 1982 2281 
mouse #11 91 423 892 1332 1562 1802 2091 2181 
mouse #12 120 209 603 1084 1245 1609 2092 2382 
mouse #13 117 488 881 1241 1522 1888 2088 2388 
mouse #14 92 462 672 996 1423 1982 1982 2452 
mouse #15 80 293 802 1128 1498 2022 2281 2408 
HT29/MDR (+ doxy) oPt 
        
day 0 3 6 9 12 15 18 21 
mouse #1 89 178 589 602 872 1172 1201 1482 
mouse #2 98 262 443 566 834 1180 1182 1478 
mouse #3 115 362 441 404 821 1182 1402 1692 
mouse #4 110 244 488 562 682 1082 1271 1680 
mouse #5 114 248 592 602 802 1084 1092 1656 
mouse #6 88 156 434 509 860 983 1002 1698 
mouse #7 82 167 489 672 892 1182 1129 1623 
mouse #8 92 209 672 802 882 1092 1371 1479 
mouse #9 108 228 502 582 673 872 1092 1692 
mouse #10 83 220 602 732 824 1088 1212 1467 
mouse #11 89 229 552 574 606 892 892 1498 
mouse #12 101 228 508 609 782 923 1243 1602 
mouse #13 108 392 593 603 800 1024 1092 1681 
mouse #14 112 221 609 609 882 988 1101 1802 
mouse #15 112 198 598 603 966 1102 1099 1802 
 
  
Additional file 12 
 
